Celgene Corporation (CELG) Wednesday announced that the Oncologic Drugs Advisory Committee of the U.S Food and Drug Administration, of the FDA, has set November 8, 2012 as the date for review of the company's New Drug Application for Pomalidomide.
The integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation, announced that it is seeking approval to market pomalidomide in combination with dexamethasone as a potential treatment for patients with relapsed and refractory multiple myeloma that has progressed following at least two prior therapies.
Pomalidomide is not approved in the U.S. for the treatment of multiple myeloma.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.